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Specific Aims 
1 . Design and synthesize specific peptide-related reversible transition-state inhibitors 
for human thrombin. 
2 . Design and synthesize heterocyclic irreversible mechanism-based thrombin 
inhibitors. 
3. Utilize molecular modeling and the x-ray structure of human thrombin to improve 
the potency and specificity of both peptide and heterocyclic inhibitors. 
4 . Evaluate the inhibitory potency and specificity of all new drugs in vitro. 
5 . Evaluate the in vivo efficacy of the antithrombotic agents in a rabbit thrombosis 
model. 
.The specific aims for the next budget period remain unchanged. 
Progress Report 
Summary. The majority of our efforts during the frrst year has been devoted to synthesis. The 
synthesis of the proposed inhibitors proved to be more difficult that we expected. Arginine related 
structures are much more time-consuming that derivatives related to other amino acids. However, only 
arginine derivatives are likely to be potent inhibitors of thrombin. We have not yet obtained new inhibitor 
structures in sufficient yields to undertake animal studies. 
Specific Aim 1-Transition-state Inhibitors. We propose to synthesize arginine a-ketoesters 
RCO-Arg-CO-OEt by a Dakin-West reaction. The design of these transition state inhibitors is based on the 
interaction of 4-amidinophenylpyruvate (APPA) with trypsin. APP A is a potent competitive inhibitor of 
trypsin, thrombin, and factor Xa with KI values of 1.6, 6.5 and 9.4 ~respectively. A refmed x-ray 
crystal structure of the complex formed by bovine trypsin and 4-amidinophenylpyruvate has been 
determined. .The amidinopheny 1 group is located in the primary specificity pocket (S I) of trypsin in 
essentially the same location as the benzamidine ring in the benzamidine-trypsin complex, the active site 
serine of trypsin has added to the 2-carbonyl group in APPA to give a "tetrahedral" structure, and the 
oxyanion is interacting with the oxyanion hole of the protease. A unique feature of this structure is the 
hydrogen bonding observed between the carboxylate oxygen and the serine oxygen and the NH of histidine-
57. 
We have tried the Dakin-West reaction with a large variety of blocked arginine derivatives as listed in 
the following table, but have yet to obtain the arginine a-ketoester product in significant yields. 
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We have abandoned the synthetic route involving direct Dakin-West reactions on arginine derivative and will 
try to synthesize the arginine derivative indirectly. We next plan to try the Dakin-West reaction on ornithine 
derivatives. We have previously obtained good yields of a-ketoester products from lysine derivatives and 
thus ornithine would also be expect to react successfully. Once the ornithine derivative is prepared, we will 
convert the ornithine side chain into an arginine side chain by amidination with 3,5-dimethylpyrazole 
carboamidine·. The synthetic routes which we will explore in the coming year are shown below. 
Z-Orn(Boc)-OH --> Z-Orn(Boc)-C02Et --> Z-Orn-C02Et --> Z-Arg-C02Et 
Z-AA-Orn(Boc)-OH --> Z-AA-Om(Boc)-C02Et --> Z-AA-Orn-C02Et --> 
Z-AA-Arg-C02Et 
Specific Aim 2-Mechanism-based Inhibitors. Isocoumarins containing basic substituents 
(aminoalkoxy, guanidino and isothiureidoalkoxy) in either the 3- or the 7-position are mechanism-based 
inhibitors for blood coagulation serine proteases and are anticoagulants in human plasma. Isocoumarins 
react initially with the active site Ser-195 to form an acyl enzyme which can deacylate to regenerate active 
enzyme. Alternately, the acyl enzyme can eliminate chlorine to form a quinone imine methide intermediate 
which can react either with a nearby enzyme nucleophile such as His-57 to give an alkylated enzyme or with 
water (or another solvent nucleophile). We propose to synthesize a number of isocoumarins with varying 
substituents of the 7 -amino group to provide specificity for thrombin and other coagulation enzymes. 
One of our major targets is compound 1 which is an analog of ACme, which we have previously 
studied in animals. This isocoumarin is projected to be more reactive than ACme. We have obtained the 
product in low yields by the route shown below, but unfortunately considerable decomposition is observed. 
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We plan to synthesize an alternate structure 2 in the coming year. This compound may be easier to 
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Specific Aim 3-X-ray Structural Studies. Dr. Wolfram Bode at the Max Planck Institute for 
Biochemistry in Munich, West Germany is trying to obtain crystals of bovine or human thrombin inhibited 
by three of our isocoumarins for x-ray crystallographic studies. Thus far, they have been unable to. obtain 
suitable crystals. Dr. Bode plans to continue efforts aimed at obtaining a crystalline derivative. In addition, 
Jay Bertrand a graduate student in the research group of Dr. Bud Suddath at Georgia Tech is carrying out x-
ray studies with trypsin inhibited by several of our isocoumarin inhibitors. He has crystals of several 
derivatives and is collecting x-ray diffraction data. The work has gone slowly due to instrument 
breakdowns. However, all the background work has been accomplished and it is likely that we will have an 
isocoumarin x-ray structure with trypsin in the next few months. We will then use it for modeling in the 
active site of thrombin. 
Specific Aim 4-In Vitro Studies. We have been carrying out kinetich studies aimed at 
preparing chemically coupled hybrids ofFab fragments and synthetic thrombin inhibitors. We plan to 
construct hybrid molecules of synthetic thrombin inhibitors coupled to Fab fragments which are directed 
against fibrin and platelets. Specifically, we will prepare and test a hybrid with a Fab molecule coupled to 
one D-FPR-CH2Cl (an irreversible thrombin inhibitor). The Fab fragments directed against fibrin and 
platelets will be prepared in the laboratory of Marshall Runge at Emory University and will contain one 
reactive thiol group in their structures. 
We have synthesized two double-headed derivatives ofD-FPR-CH2Cl (D-Phe-Pro-Arg-CH2Cl) 
and worked out the procedure for coupling these derivatives to the thiol group of proteins using albumin as 
a model system. The two double headed derivatives are ClCH2-Arg<-Pro<-D-Phe-CO-CO-D-Phe-Pro-
Arg-CH2Cl and ClCH2-Arg<-Pro<-D-Phe<-CO-(CH2)3-CO-D-Phe-Pro-Arg-CH2Cl (<-indicates a 
reversed peptide chain). The first inhibitor was prepared by reacting D-FPR(Tos)-CH2Cl with oxalyl 
chloride to give [-CO-D-FPR(Tos]-CH2Cl]2 which was then deblocked with anhydrous HF and purified on 
SE-Sephadex. The second double headed chloromethyl ketone molecule ClCH2-Arg<-Pro<-D,.Phe<-CO-
(CH2)3-CO-D-Phe-Pro-Arg-CH2Cl was synthesized similarly by reacting D-FPR(Tos)-CH2Cl with 
glutaryl dichloride followed by deblocking. Both double headed molecules are potent irreversible thrombin 
inhibitors, although neither is as reactive as the parent D-FPR-CH2CL The synthetic work was carried out 
prior to the initiation of this grant by a postdoc supported by an industrial training grant. 
Coupling of each inhibitor to the thiol group of albumin was carried out by reacting an excess of the 
double headed inhibitor with albumin in a 0.1 M N aHC03, pH 8.1 buffer. By thiol titration, we found that 
respectively 45% and 40% of the thiol groups in albumin reacted with the double headed D-FPR-CH20 
inhibitors to give adduct I and adduct II. Both adducts I and II inhibit thrombin quite potently with second 
order inhibition rates of 29,000 and 78,000 M-ls-1 respectively. Adduct II has the structure albumin-S-
CH2-Arg<-Pro<-D-Phe<-CO(CH2)3-CO-D-Phe-Pro-Arg-CH2Cl where a tripeptide-glutaryl spacer links 
one reactive D-FPR-CH2Cl molecule to the thiol group of albumin. This spacer is more flexible than the 
one in adduct I and this is likely the reason for the 3 fold higher inhibition rate with thrombin by adduct II. 
Adduct II is very stable in 0.1 M Hepes, pH 7.5 buffer and has a half-life of 3 days. These experiment 
clearly demonstrate that we can covalent link synthetic thrombin inhibitors to thiol groups in proteins and 
produce stable protein adducts which contain potent thrombin inhibitors. We propose to use these same 
reactions to prepare adducts of antiplatelet and antifibrin Fab fragements with both double headed thrombin 
inhibitors. We have now obtained the Fab fragment and will carry out these experiments in the near future. 
Specific Aim 5-Vertebrate Animal Studies. Since none of the synthetic work has yet been 
completed, no animal work was carried out during the frrst year of this research. We plan to carry out the 
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